Johnson & Johnson delivered robust quarterly earnings that surpassed Wall Street expectations, driven by exceptional performance from its pharmaceutical division. The healthcare giant's medicines unit demonstrated strong market momentum, contributing significantly to overall revenue growth. Building on this success, J&J has raised its full-year guidance for both sales and profitability, signaling management confidence in sustained business momentum. This positive outlook reflects successful product launches and steady demand across key therapeutic areas.

Summary auto-generated by AI from the original publisher's content. Editorial standards.